USE OF PROTEINS AS AGENTS AGAINST AUTOIMMUNE DISEASES

Abstract: The use of proteins extracted with perchloric acid from animal organs, for the preparation of medicaments active against autoimmune diseases, in particular with activity against atherosclerosis, arthritis, multiple sclerosis, diabetes.

Description: USB QP PROTEIHS AS AGENTS AGAINST AUTOIMMUNE DISEASES The present invention relates to the use of proteins extractable from animal organs, particularly from livers of mammals, for the preparation of medicaments active against autoimmune diseases, in particular activity against atherosclerosis, arthritis, multiple sclerosis, diabetes. The administration of complete Preund's adjuvant has proved to be capable of inducing an experimental arthritis very similar to rheumatoid arthritis in rats. On the other hand, the administration of adjuvant to rabbits induces no arthritic pathology, but atherosclerosis. The studies carried out have evidenced that, in both lesions, immunoreactivity to an endogenous factor, which has been identified as the Heat Shock Protein 60 (HSP60), is present. Subsequent searches have confirmed these observations, proving that the administration of complete Preund's adjuvant can be replaced by the administration of HSP60 , resulting in the same pathologies. Afterwards, pre-trβatment of rat with adjuvant, HSP60 or fragments thereof has proved to prevent the onset of arthritis, with a still obscure mechanism, whereas the administration subsequent to the adjuvant worsens the progress of the disease. More recently, pre-treatment with adjuvant has been found to also prevent other experimental pathologies which can be defined, generally speaking, as autoimmune disease, such as diabetes or experimental allergic encephalomyelitis (EAE). Finally, HSP60 has been found to have structural analogies to a high number of CONFIRMATION COP/ autoantigens, therefore it is assumed to be related to pathologies more widely than what up to now observed. WO 92/10197 disclosed protein fractions extractable with perchloric acid from organs of mammals, and their use as anticancer agents. Within these fractions, three main components could be identified, having molecular weights 50, 14 and 10 KDa on gel electrophorβsis. The purified extract containing these three components will be referred to as UK 101 in the following. The sequence of the 14 KDa protein component, which is the main, if not the only, responsible for the described activities, is reported in the Table hereinbelow and in WO 96/02567, and it has turned out to be related to that described by other authors (Levy-Favatier , Eur. Biochem. 1903, 212 (3) 665-73) which have assumed that the novel identified sequences belong to the family of the proteins known as chaperonins, to which the HSPs themselves belong. The proteins described in WO 92/10197 and those of WO 96/02567 (in the following referred to as UK 114) show anyhow properties never observed for chaperonins or analogous proteins. More specifically, it has been found that said proteins can be used in the prevention and in the treatment of autoimmune diseases, in particular atherosclerotic conditions, such as the atherosclerosis induced by organ transplants, arthritis, multiple sclerosis and diabetes. The invention relates preferably to the use of the purified proteins UK 101 and UK 114 for the preparation of medicaments for the prevention and the treatment of autoimmune diseases such as atherosclerosis following organ transplants, arthritis, multiple sclerosis, diabetes. Moreover the invention comprises the use of proteins showing a high homology degree to UK 114, of at least 80%, preferably of at least 90%. ANTTATHEROSC RROTTC ACTIVITY It has been ascertained that nowadays the more * frequent cause of failure of organ transplants in time is no more the rejection, but the formation of atherosclerotic plaques at the contact point between the vases of the transplanted organ and those of the host. This pathology is worsened by the usual immunosuppressors such as cyclosporin, whereas the use of AZT, which is however very toxic, appears to be useful. The activity of the proteins UK 101 and UK 114 has been evidenced using both a conventional atherosclerosis model, which is that of the rabbit pre-treated with complete Freund'ε adjuvant, and a transplant atherosclerosis model. In the first case, the subcutaneous treatment with adjuvant induces within 21 days the formation of atherosclerotic plaques at the iliac bifurcation and at the aortic arch. The pre- treatment (7 days before) with UK 101 or UK 114 has significantly prevented the development of the pathology in a high percent of cases compared with the treatment with the only adjuvant, which has lead to the development of the disease in all of the animals. On the other hand, the experimental model of transplant atherosclerosis consists in the venous by- passes at the level of arteries in the rat. After a short time, the formation of atherosclerotic plaques at the level of the host vase, as it happens in the human pathology, has been observed. The pre-treatment (7 days before) with UK 101 or UK 114 has significantly prevented the development of the pathology in a high percent of cases, compared with what observed in the animals non pre-treated before the transplant. ANTIARTHRITIS ACTIVITY This activity has been evidenced using a conventional arthritis model, which is the adjuvant- induced arthritis. In this model, Lewis rats are injected at the tail base with complete Preund's adjuvant: within 7 days, a pathology at the rear leg appears, characterized by swelling and joints alterations. The pathology reaches its peaks fron the 14th to the 21εt day, then decreasing until the leg returns to normal conditions. The pre-treatment (7 days before) with UK 101 or UK 114 has εignificantly prevented the development of the pathology in a high percent of cases compared with treatment with the only adjuvant, which has lead to the development of the pathology in 100% of the animals. The treatment with UK 101 or UK 114 after the administration of adjuvant has worsened the progress of the pathology. Therefore, it is considered that UK 101 and UK 114 are capable of modifying the progress of or of preventing pathological conditions such as arthritis and rheumatoid arthritis. ACTIVITY AGAINST MULTIPLE SCLEROSIS This has been evidenced using a conventional multiple sclerosis model: the experimental allergic encephalomyelitiε (EAE). The pathology is induced injecting subcutaneouεly Lewis rats with a Guinea-pig spinal cord homogenate together with complete Preund's adjuvant. The pathology appears as a progressive paralysis starting from the rear limbs, which begins at about the 12th day, reaches a maximum at about the 21st day and undergoes remission at about the 30th day from the administration of the im unogen. The pre-treatment (7 days before) with UK 101 or UK 114 has significantly prevented the development of the pathology in a high percent of caseε and a less serious pathology has appeared, compared with treatment with the only marrow homogenate and adjuvant, which has lead to the development of the pathology in 100% of the animals. Therefore UK 101 and UK 114 are believed to be able of changing the progress of or preventing pathological conditions such as multiple sclerosis. AN TnTARETTC ACTIVITY This has been evidenced using a conventional diabetes model, represented by the BB rat which spontaneously develops diabetes around the 45th day of life. The animals have been treated at the 30th day of life with UK 101 or UK 114 and the development of the pathology has been observed, compared with untreated control animals. The pre-treatment has been found to decrease the incidence and the severity of the pathology in the experimental model. Some patients affected with tumors at different sites and also suffering from diabetes have been treated with UK 101 in the course of a compassionate treatment with the subεtance. All of the patients treated, independently of the effect on the tumor pathology, have εhown a remission of the diabetic pathology going so far as to quit the insulin therapy. Therefore UK 101 and UK 114 are believed to be capable of changing the course of diabetes or of preventing it. The antidiabetic activity has in fact been confirmed, although up to now in a limited number of cases, also n vivo in patients suffering from diabetes. The proteins of the invention can be administered using suitable formulations, mainly injectablβ. The pattern of the administration (doses, frequency of administration, etc.) will be determined according to the circumstances, depending on factors such as conditions of the patient, phase of the disease, etc., but usually a daily dosage ranging from 1 to 100 mg will be suitable. TABLE Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lyε Ala 1 5 10 Pro Ala Ala lie Gly Pro Tyr Ser Gin Ala Val Leu Val Asp 15 20 25 Arg Thr lie Tyr lie Ser Gly Gin Leu Gly Met Asp Pro Ala 30 35 40 Ser Gly Gin Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys 45 50 55 Gin Ala Leu Thr Asn lie Gly Glu lie Leu Lyε Ala Ala Gly 60 65 70 Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala 75 80 Asp lie Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gin 85 90 95 Tyr Phe Gin Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gin Val 100 105 110 Ala Ala Leu Pro Lys Gly Gly Arg Val Glu lie Glu Ala lie 115 120 125 Ala Val Gin Glv Pro Leu Thr Thr Ala Ser Val 130 135 SEQUENCE LI STING ( 1 ) GENERAL INFORMATION : ( i ) APPLICANT : (A) NAME: zetesiε s.p.a. (B) STREET: Galleria del Corso 2 (C) CITY: Milano (E) COUNTRY: Italy (F) POSTAL CODE (ZIP): 20122 (ii) TITLE OF INVENTION: Use of proteins as agents against autoimmune diseases (iii) NUMBER OF SEQUENCES: 1 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 137 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Met Ser Glu Aεn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala 1 5 10 Pro Ala Ala He Gly Pro Tyr Ser Gin Ala Val Leu Val Asp 15 20 25 Arg Thr He Tyr He Ser Gly Gin Leu Gly Met Asp Pro Ala 30 35 40 Ser Gly Gin Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys 45 50 55 Gin Ala Leu Thr Asn He Gly Glu He Leu Lyε Ala Ala Gly 60 65 70 Cys Asp Phe Thr Asn Val Val Lyε Ala Thr Val Leu Leu Ala 75 80 Aεp He Aεn Aεp Phe Ser Ala Val Aεn Aεp Val Tyr Lyε Gin 85 90 95 Tyr Phe Gin Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gin Val 100 105 110 Ala Ala Leu Pro Lyε Gly Gly Arg Val Glu He Glu Ala He 115 120 125 Ala Val Gin Gly Pro Leu Thr Thr Ala Ser Val 130 135

Claims: CLAIMS 1. The uεe of proteins extractable with perchloric acid from mammal liver, for the preparation of medicaments active against autoimmune diseases. 2. The use according to claim 1, wherein the protein has the following sequence: Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lyε Ala 1 5 10 Pro Ala Ala He Gly Pro Tyr Ser Gin Ala Val Leu Val Asp 15 20 25 Arg Thr He Tyr He Ser Gly Gin Leu Gly Met Asp Pro Ala 30 35 40 Ser Gly Gin Leu Val Pro Gly Gly Val Val Glu Glu Ala Lyε 45 50 55 Gin Ala Leu Thr Asn He Gly Glu He Leu Lyε Ala Ala Gly 60 65 70 Cys Aεp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala 75 80 Aεp He Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gin 85 90 95 Tyr Phe Gin Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gin Val 100 105 lio Ala Ala Leu Pro Lys Gly Gly Ar 8g Val Glu He Glu Ala He 115 120 125 Ala Val Gin Gly Pro Leu Thr Thr Ala Ser Val 130 135 3. The use according to claim 1, wherein the proteins uεed have a homology of at leaεt 80% to the protein of claim 2. 4. Pharmaceutical compositions containing as the active ingredient the proteins of claims 1-3 in admixture with suitable excipients. 5. The uεe according to claim 1, for the preparation of medicamentε for the prevention and the treatment of atherosclerosis following transplants. 6. The uεe according to claim 1, for the preparation of medicaments for the prevention and the treatment of arthritis . 7. The uεe according to claim 1, for the preparation of medicaments for the prevention and the treatment of multiple εclerosis. 8. The use according to claim 1, for the preparation of medicamentε for the prevention and the treatment of diabetes.

Inventors: BARTORELLI ALBERTO, PANERAI ALBERTO E, BARTORELLI, ALBERTO, PANERAI, ALBERTO, E.
Applicants: BARTORELLI ALBERTO, PANERAI ALBERTO E, ZETESIS SPA, BARTORELLI, ALBERTO, PANERAI, ALBERTO, E., ZETESIS S.P.A.
Application year: 1997
Main classification: A61K38
IPC codes: A61K38, A61P3, A61P19, A61P37, C07K14